Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) was downgraded by stock analysts at Maxim Group from a “buy” rating to a “hold” rating in a research report issued on Thursday. Get Capricor Therapeutics alerts:Check Out Our Latest Analysis on CAPRCapricor Therapeutics Stock Up 1.5%CAPR stock opened at $6.67 on Thursday. Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last released its earnings results on Tuesday, May 12th. As a group, analysts anticipate that Capricor Therapeutics will post -0.49 earnings per share for the current fiscal year. Recommended StoriesReceive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.